MADRIGAL PHARMACEUTICALS, INC.
Ownership & governance
Executives 5Directors 8Avg age 61Avg tenure 3.8y
WS
William Sibold
Chief Executive Officer
Age 59Since 2023-09-07Profile →
+12
Executives5
WS
William Sibold→
Chief Executive Officer
Age 59Since 2023-09-07
MD
Mardi Dier→
Director of Finance/CFO
Age 62Since 2024-03-10
DS
David Soergel→
Chief Tech/Sci/R&D Officer
Age 58Since 2025-04-20
MU
Mark Underwood
Chief Operating Officer
—Since 2023-12-31
RF
Ronald Filippo
Chief Tech/Sci/R&D Officer
—Since 2023-11-20
Board of directors8
RT
Rebecca Taub→
Director/Board Member
Age 74Since 2016-06-30
RL
Richard Levy→
Director/Board Member
Age 68Since 2016-08-10
JD
James Daly→
Director/Board Member
Age 64Since 2019-06-26
JB
Julian Baker→
Chairman
Age 59Since 2023-06-14
RC
Raymond Cheong→
Director/Board Member
Age 44Since 2023-06-14
WS
William Sibold→
Director/Board Member
Age 59Since 2023-09-07
JF
Jacqualyn Fouse→
Director/Board Member
Age 64Since 2025-03-10
DB
Daniel Brennan→
Director/Board Member
Age 60Since 2025-08-04
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Baker Bros. Advisors LP | 9.337 % | 2,152,597 |
| Baker Bros. Advisors LP | 9.289 % | 2,141,701 |
| Janus Henderson Investors US LLC | 8.774 % | 2,022,885 |
| RTW Investments LP | 8.647 % | 1,993,687 |
| Avoro Capital Advisor LLC | 7.886 % | 1,818,181 |
Catalog · 2026-07-09
Proxy officers27
| Name | Role | Since | Shares |
|---|---|---|---|
| Julian Baker | Chairman | 2023-06-14 | - |
| Bill Sibold | Director or executive officer | 2023-09-01 | 24,195 |
| Carole Huntsman | Director or executive officer | — | 11,236 |
| Carole Huntsman | Director or executive officer | — | 11,236 |
| Daniel Brennan | Director/Board Member | 2025-08-04 | - |
| David Soergel, M.D | Director or executive officer | — | 5,096 |
| David Soergel, M.D | Director or executive officer | — | 5,096 |
| Jacqualyn Fouse | Director/Board Member | 2025-03-10 | - |
Proxy · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 682.11Range 543–962Analysts 18
543Mean 682.11962
- Strong buy 3
- Buy 15
- Hold 1
Broker actions40 of 141
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Citigroup | Initiated | Buy | 725 | 2026-09-23 |
| Wolfe Research | Upgrade | Outperform | 605 | 2026-08-04 |
| Barclays | Maintained | Overweight | 962 | 2026-08-03 |
| Canaccord Genuity | Maintained | Buy | 587 | 2026-07-29 |
| Wells Fargo | Initiated | Overweight | 685 | 2026-07-27 |
| B of A Securities | Maintained | Neutral | 542 | 2026-06-11 |
| Truist Securities | Maintained | Buy | 709 | 2026-05-13 |
| Canaccord Genuity | Maintained | Buy | 578 | 2026-05-07 |
| Evercore ISI Group | Maintained | Outperform | 649 | 2026-05-07 |
| HC Wainwright & Co. | Reiterated | Buy | 620 | 2026-05-06 |
| B of A Securities | Maintained | Neutral | 529 | 2026-02-20 |
| Barclays | Initiated | Overweight | 964 | 2026-01-28 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.